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ABSTRACT
The host restriction factor Apobec3G is a cytidine
deaminase that incorporates into HIV-1 virions and
interferes with viral replication. The HIV-1 accessory
protein Vif subverts Apobec3G by targeting it for
proteasomal degradation. We propose a model in
which Apobec3G N-terminal domains symmetrically
interact via a head-to-head interface containing
residues 122 RLYYFW 127. To validate this model
and to characterize the Apobec3G–Apobec3G and
the Apobec3G–Vif interactions, the mammalian
protein–protein interaction trap two-hybrid tech-
nique was used. Mutations in the head-to-head
interface abrogate the Apobec3G–Apobec3G inter-
action. All mutations that inhibit Apobec3G–
Apobec3G binding also inhibit the Apobec3G–Vif
interaction, indicating that the head-to head inter-
face plays an important role in the interaction
with Vif. Only the D128K, P129A and T32Q mutations
specifically affect the Apobec3G–Vif association.
In our model, D128, P129 and T32 cluster at
the edge of the head-to-head interface, possibly
forming a Vif binding site composed of two
Apobec3G molecules. We propose that Vif either
binds at the Apobec3G head-to-head interface
or associates with an RNA-stabilized Apobec3G
oligomer.
INTRODUCTION
Eﬃcient replication of lentiviruses, such as HIV-1,
requires the viral infectivity factor Vif. HIV-1 viruses
deﬁcient in Vif are unable to form infective particles
in non-permissive cells due to the host restriction
factor Apolipoprotein B messenger RNA (mRNA)-
editing catalytic polypeptide-like 3G (Apobec3G) (1).
Apobec3G and the closely related Apobec3F are incorpo-
rated into the virions of Vif-deﬁcient HIV-1 and restrict
the virus (1,2). Apobec3G contains two zinc-binding
deaminase domains: the N-terminal domain binds to
RNA, while the C-terminal domain is responsible for the
DNA-binding and DNA-editing cytidine deaminase
activity (3,4). Upon reverse transcription of the HIV-1
RNA, Apobec3G deaminates deoxycytidine to deoxyuri-
dine in the nascent DNA minus strand (5). The resulting
plus strand contains multiple dG to dA mutations, leading
to premature stop codons and other aberrant viral tran-
scripts (6,7). However, Apobec3G and Apobec3F do not
strictly require cytidine deaminase activity for their
antiviral eﬀect (8,9). Apobec3G binding to the viral
RNA partially inhibits the reverse transcription process,
probably by inhibiting complementary DNA (cDNA)
elongation (10). Apobec3G is packaged into viral particles
via interactions with the nucleocapsid domain of the gag
polyprotein and this interaction probably requires host or
viral RNA (11–13). HIV Vif prevents the incorporation of
Apobec3G and Apobec3F into the virions, thus restoring
virus infectivity (14–16). Vif contains a C-terminal
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C, cullin 5 and rbx1, leading to formation of an E3
ubiquitin ligase complex (17,18). Vif binding
to Apobec3G results in ubiquitination and proteasomal
degradation of Apobec3G. Therefore, inhibitors of the
Apobec3G–Vif interaction may restore the antiviral
eﬀect of Apobec3G and could oﬀer a novel mechanism
for therapeutic intervention for HIV-1 (19,20).
Apobec3G and Apobec3F belong to the Apobec3
family which consists of 7 members (20,21). Apobec3A,
C and H contain a single deaminase domain, where
Apobec3B, DE, F and G contain tandem duplications of
a deaminase domain with a similar sequence. The struc-
ture of the C-terminal domain of Apobec3G was deter-
mined by X-ray crystallography and nuclear magnetic
resonance (NMR). This domain folds into a ﬁve-stranded
central beta sheet, surrounded by six alpha helices (22–24).
The X-ray crystallography structure of Apobec2, which
resembles the structures of the Apobec3 C-terminal
domain, revealed the formation of tetramers. Apobec2
dimers occur via pairing of the b strand 2 and subsequent
head-to-head interaction of two dimers results in the for-
mation of Apobec2 tetramers (25).
The N-terminal domain of Apobec3G has no cytidine
deaminase activity but binds RNA and the HIV gag
nucleocapsid and mediates packaging of Apobec3G in
the virion (3,4,26,27). An 80-amino-acid sequence
comprising the putative zinc-coordinating motif in this
N-terminal domain was shown to be important for
binding of Vif (28). Residues Y124 and W127 in the
N-terminal domain are important for this packaging
process (29). Diﬀerent models have been proposed for
the N-terminal domain of Apobec3G (30,31) or for
complete Apobec3G (24,27). In these models, residues
124 and 127 are surface-exposed in the monomeric
N-terminal domain. In a recent model (27), the N-and
C-terminal domain of an Apobec3G monomer are
proposed to interact with each other via their b2 strand
as in the Apobec2 dimer interface. Two studies propose
that the N-terminal domains of Apobec3G further interact
with each other as in the Apobec2 head-to-head interface
(27,31). Residues 122–127 maintain important interactions
in this head-to-head interface, and the interaction is
stabilized by RNA which binds to a cluster of positively
charged residues at one edge of the head-to-head interface
(27). The structure of Vif remains unsolved and it is thus
far unknown how Vif interacts with Apobec3G. In this
article, we study the Vif and Apobec3G interactions
using the mammalian protein–protein interaction trap
(MAPPIT) mammalian two-hybrid system (32,33),
site-directed mutagenesis and homology modeling. Our
study provides new information on detailed interfaces
that govern the Apobec3G–Apobec3G and Apobec3G–
Vif interactions.
MATERIALS AND METHODS
Cell culture, transfection and reporter assays
Culture conditions, transfection procedures and luciferase
assays in Hek293T cells were as previously described (34).
For a typical luciferase experiment, Hek293T cells were
seeded in six-well plates 24h before overnight transfection
with the desired constructs together with the luciferase
reporter gene. Twenty-hour hours after transfection,
cells were washed, trypsinized and seeded into 96-well
plates. The seeded cells were left untreated or were
stimulated with 0.5IU/ml hEpo overnight. The luciferase
activity of the transfected cells was measured by
chemiluminescence.
Constructs
All constructs were obtained by standard polymerase
chain reaction (PCR)- or restriction-based cloning proce-
dures. The pXP2d2-rPAPI-luciferase reporter, originating
from the rPAPI (rat pancreatitis associated protein
I) promoter was described earlier (32). Generation of the
standard chimeric bait receptor pCEL, containing the
extracellular part of the EpoR and the intracellular part
of the leptin receptor and standard chimeric prey receptor
pMG2, containing part of the gp130 chain (amino acids
905–918) in duplicate, were previously reported (32,35,36).
The pMet7Flagtag vector, the pMet7Etag vector and the
pMet7EtagCIS construct were previously described
(34,37).
Human peripheral blood leukocyte (PBL) cDNA was
purchased from PrimGen. The pNL4-3 Plasmid which
carries the full HIV-1 genome was a gift from Prof.
C. Verhofstede. The pCMV4-HA-A3G-L123A and
pCMV4-HA-A3G-Y124A mutants were kindly provided
by Prof. M. Malim and Dr H. Huthoﬀ. The
VifSLQ144-146AAA prey (represented as VifSLQ prey)
used in Figure 3C was created as stated in the table in
the Supplementary Data. A human codon optimized
VifSLQ prey was purchased from GENEART
(represented in Supplementary Data) and was used in
Figures 3D, 6 and 9 and most of the data represented in
Table 1. All other constructs used in this paper are created
as represented in the table in the Supplementary Data.
Western blot analysis and degradation assay
Protein expression levels in MAPPIT assays and degrada-
tion assays were conﬁrmed by western blot analysis.
Transfected Hek293T were lysed in RIPA buﬀer
[200mM NaCl, 50mM Tris–HCl pH 8, 0.05% sodium
dodecyl sulfate (SDS), 2mM EDTA, 1% NP40, 0.5%
DOC, Complete
TM Protease Inhibitor Cocktail (Roche)].
Then 4X loading buﬀer (125mM Tris–HCl pH 6.8,
6% SDS, 20% glycerol, 0.02% BFB, 10% b-mercapto-
ethanol) was added to the lysates. Samples were heated
and then loaded on a 7.5 or 10% polyacrylamide gel
and blotted onto nitrocellulose membrane. Blotting eﬃ-
ciency was checked using PonceauS staining (Sigma).
FLAG-tagged, E-tagged and V5-tagged proteins (data
not shown) were revealed using monoclonal anti-Flag
antibody M2 (Sigma), monoclonal anti-E-tag antibody
(Amersham Biosciences) and monoclonal anti-V5-tag
antibody (invitrogen). Secondary anti-mouse-DyLight800
or 680 antibodies (Thermo Scientiﬁc) were used and
western blot analysis was performed using the Odyssey
Infrared Imaging System (Li-Cor).
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Alpha screen experiments were conducted according to
the manufacturer’s protocol (PerkinElmer). Typically,
cells were co-transfected overnight with the appropriate
E- and Flag-tagged expression vectors, washed after
24h and lysed 24h later (lysis buﬀer: 50mM Tris–HCl
pH 7.5, 125mM NaCl, 5% glycerol, 0.2% NP40, 1.5mM
MgCl2, 25mM NaF, 1mM Na3VO4, Complete
TM
Protease Inhibitor without EDTA Cocktail). Lysates
were cleared by centrifugation. Streptavidin donorbeads
and anti-Flag acceptorbeads were added together with
biotinylated anti-Etag antibody and the appropriate
amount of RNAse A (Roche) and incubated for at least
2h under constant rotation. Samples were measured in
triplicate using the EnVision platereader (PerkinElmer).
The anti-Etag antibody (Amersham Biosciences) was
biotinylated with sulfo-NHS-Biotin (PIERCE) according
to the manufacturer’s guidelines.
Homology modeling
The Apobec3G N-and C-terminal domains were aligned
to all human Apobec domains, using Multiple Alignment
using Fast Fourier Transform (MAFFT) (38). The struc-
tures of Apobec2 and the C-terminal domain of
Apobec3G were superposed and aligned to this MAFFT
alignment in MOE (molecular operating environment,
chemical computing group). Based on the superposition,
the MAFFT alignment was edited. Using this edited align-
ment as input, homology models were built using
MODELLER 9v7 (39) and alternative models were built
in MOE. Both types of models were compared. A dimer
model was built for the Apobec3G N-terminal domain
using the structure of Apobec2 as template. For the
dimer model, symmetry restraints were used for
the backbone atoms of domains that interact via the
head-to-head interface. The MODELLER models with
the best DOPE score and the lowest energy MOE
models were further subjected to conjugate gradients
energy minimization using the OPLS/AA force ﬁeld in
MOE. The model protein geometry quality was assessed
in MOE. Solvent accessibility of the models was deter-
mined using NACCESS (Hubbard,S.J. and Thornton,
J.M. (1993), ‘NACCESS’, Computer Program, Depart-
ment of Biochemistry and Molecular Biology, University
College London.).
RESULTS
Homology model of the N-terminal domain of Apobec3G
Homology models were built for the N-terminal domain
of Apobec3G using the crystal structure of Apobec2
as template. In the crystal structure, Apobec2 forms
tetramers. Two monomers dimerize via pairing of the b
strand 2 with formation of an extended beta sheet. These
dimers subsequently form a tetramer by head-to-head
interactions of two dimers with symmetric interactions
via helix 4 and 6 and via the loops between helix1 and b1
and between b4 and helix 4. Models were built for a
head-to-head interaction of two Apobec3G N-terminal
domains (Figure 1A). In the MODELLER models, the
indole groups of W94 and W127 of both monomers
stack against each other. During OPLSA/AA energy min-
imization, the guanidinium group of R122 intercalates
between both indole groups (Figure 1B). Another interac-
tion in the interface is formed by the aromatic rings of
tyrosines 124 and 125 of both monomers, which stack on
top of each other, and tyrosine 125 in both monomers
interact symmetrically (Figure 1C). D128 is buried in our
model and D128 of one monomer forms a hydrogen bond
network with Y22, Y125 and W94 of the other monomer
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Figure 1. Homology model of the Apobec3G N-terminal deaminase domain. A dimer of two N-terminal domains (red and blue), interacting via the
122–127 motif is shown. (A) Overview with indication of secondary structure elements. (B–D) Detail of selected sidechain interactions between the
diﬀerent monomers.
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hydrogen bond is formed between D128 and R24.
Two conserved protein interfaces in Apobec3G and
Apobec3F
We compared the sequences of human Apobec3G and
Apobec3F. The entire head-to-head interface area
around W127 is nearly identical in Apobec3G and
Apobec3F (Figure 2A). Apobec3G and Apobec3F may,
therefore, homodimerize in a very similar way. This inter-
face is possibly involved in RNA-dependent Apobec3G–
3F heterodimerization (16,40). The conserved zone
consists of two major subzones: a ﬁrst subzone is
centered around the 122 RFYYW 127 motif and forms
the core of the head-to-head interface, a second subzone in
the N-terminal domain contains residues such as Y19,
Y22, R24 and T32, and extends beyond this modeled
dimer interface. Another zone of identical surface
residues is found around b strand 2 (Figure 2B and C).
As b strand 2 forms a dimer interface in the Apobec2
crystal structure, it is possible that b strand 2 in the
Apobec3G and Apobec3F N-terminal domain is similarly
involved in dimerization.
MAPPIT analysis of Apobec3G–Apobec3G and
Apobec3G–Vif interactions
We tested the importance of the predicted head-to-head
interface for the Apobec3G–Apobec3G and Apobec3G–
Vif interactions using the MAPPIT conﬁguration shown
in Figure 3A (32). In MAPPIT, a bait protein is coupled to
the C-terminus of a chimeric protein that consists of the
extracellular and transmembrane domain of the
erythropoietin receptor (EpoR) and the intracellular
domain of the leptin receptor (LepR). The tyrosine
residues in the leptin receptor domain are mutated to
phenylalanine, thereby preventing the chimera from
inducing JAK/STAT signaling. The prey is coupled to a
duplication of a fragment of the gp130 receptor. When
bait and prey interact, and the receptor is stimulated
with Epo, the gp130 tyrosines are phosphorylated by the
activated JAK2 in the bait construct. The phosphorylated
tyrosines in the prey then recruit STAT3, which in turn is
phosphorylated. Activated STAT3 is translocated to the
nucleus where it induces expression from a luciferase
reporter. We ﬁrst tested whether we could detect an inter-
action using Apobec3G and Vif as bait or prey.
Apobec3G cloned as bait shows a clear MAPPIT interac-
tion with Vif or Apobec3G cloned as prey (Figure 3B).
The loss-of function mutants Vif C133S and Vif
SLQ144-146AAA were previously shown to disrupt
Apobec3G ubiquitination and degradation, whereas
these mutants retain their interaction with Apobec3G
(17,41). Introduction of the SLQ144-146AAA and
C133S mutations in the Vif prey resulted in increased
MAPPIT signals (Figure 3C). In the following studies,
we used the Vif SLQ144-146AAA mutant prey (VifSLQ
prey) in our MAPPIT conﬁguration to study the
Apobec3G–Vif interaction.
Next, we validated our method for studying mutations
that disrupt protein interactions. D128 of Apobec3G was
previously reported to be involved in Vif association (29).
We introduced the D128K mutation in our Apobec3G
bait construct and veriﬁed the eﬀect on VifSLQ prey
association. The Vif–Apobec3G interaction was clearly
abrogated by the D128K mutation in Apobec3G
(Figure 3D).
Mutations in the predicted head-to-head interface aﬀect
the Apobec3G homodimerization interaction
In the Apobec3G–Apobec3G interaction model, W94,
R122, Y124, Y125 and W127 play an important role in
maintaining the interaction at the dimer interface. We
mutated these residues in the Apobec3G bait and/or prey
and tested the eﬀect of the mutations on the Apobec3G–
Apobec3G interaction. All mutations clearly disrupt the
interaction, supporting the hypothesis that the mutated
residues are involved in mediating the Apobec3G–
Apobec3G interaction (Figure 4). In addition, we used
alphascreen
TM technology (PerkinElmer) to test the eﬀect
of the W127A and D128K mutations. A strong
alphascreen signal was detected between E-tagged and
Flag-tagged Apobec3G, which was abrogated by the
addition of RNAse A indicating that the
Apobec3G-Apobec3G interaction is RNA mediated
(Figure 5). The W127A mutation strongly decreased the
alphascreen
TM signal, supporting an important role of
Figure 2. Model of the Apobec3G N-terminal domain. Residues which are identical in the N-terminal domain of Apobec3F are colored green.
(A) A ﬁrst identical area includes the 122–127 motif. (B) By turning the model 90 around the Y-axis, a second identical area appears. (C) Ribbon
presentation with model orientation as in (B). The identical area in (B) coincides with the b-2 strand.
Nucleic Acids Research,2010, Vol.38, No. 6 1905W127 in homodimerization, as predicted from the analysis
of the modeled interface. The D128K mutation did not
inhibit Apobec3G–Apobec3G interaction in a MAPPIT
experiment or alphascreen
TM setup (Figures 4 and 5).
Mutations in the predicted Apobec3G–Apobec3G
head-to-head interface aﬀect the interaction with Vif
We next determined the eﬀect of mutations in the pre-
dicted interface on the Apobec3G–Vif interaction using
MAPPIT with the Apobec3G mutants as bait and
VifSLQ as prey. Mutations of R122, Y124 and Y125,
W94 or W127 in the predicted Apobec3G interface
completely abolished the interaction with the VifSLQ
prey (Figure 6). These data suggest that the residues in
the predicted interface are important for both the interac-
tion with Apobec3G and interaction with Vif.
For eight diﬀerent Apobec3G mutants, we compared the
interaction with Vif and VifSLQ preys. Similar results were
obtainedwithbothVifandVifSLQpreys,justifyingtheuse
of VifSLQ preys in this study (data not shown).
Eﬀect of extensive mutagenesis of the Apobec3G–
Apobec3G head-to-head interface
Mutations of W94, R122, Y124 and Y125 or W127
disrupt both the Apobec3G–Apobec3G interaction and
the Apobec3G–Vif interaction, suggesting that both
interactions are functionally coupled. We created point
mutations in the entire area around the model interface
and compared the eﬀect of the mutations on both inter-
actions. Table 1 summarizes the results of these experi-
ments. The eﬀect of the mutations was mapped in color
code on the Apobec3G model (Figures 7 and 8). The data
show a patch of residues Y22, R24, R29, R30, W94, R122,
Y125, W127 and Y181 that strongly aﬀect the Apobec3G–
Apobec3G interaction when mutated. Comparison of
Figure 8A and B shows that all mutations that aﬀect the
Apobec3G– Apobec3G interaction also aﬀect the
Apobec3G–VifSLQ interaction. These data conﬁrm that
the predicted interface is important for mediating both
protein–protein interactions.
P129 and T32 are possibly part of a Vif-binding site at
the edge of the Apobec3G–Apobec3G interface
HIV Vif cannot bind Apobec3G of some nonhuman
primate species. A single D128K mutation found in
Apobec3G of African green monkeys abrogates the
binding of Vif and subsequent degradation (42–45).
D128 is proposed to be part of a Vif-binding site and is
surface exposed in diﬀerent models of the Apobec3G
N-terminal domain (27,30). Mutation of residues D128,
P129 or D130 protects Apobec3G against Vif-mediated
degradation, and these residues have been proposed as a
possible Vif interaction site (29,42–45). In our MAPPIT
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Figure 3. (A) The MAPPIT technique is based on signal transduction of the leptin receptor. The extracellular and transmembrane part of the Epo
receptor is fused to the intracellular part of the leptin receptor. The membrane-distal tyrosine at position Y1138 in the cytoplasmic tail of the
receptor is replaced by phenylalanine to prevent STAT3 recruitment. The two membrane-proximal tyrosines Y985 and Y1077 are mutated to
overcome negative regulation and maximize the intensity of the signal. The bait protein is attached to this signaling-deﬁcient leptin receptor. The
prey protein is fused to several STAT3 recruitment sites of the gp130 chain. Interaction of bait and prey proteins results in STAT3 recruitment and
activation. A STAT3-responsive luciferase reporter gene allows detection of the interaction. (B–D) Hek293T cells were transiently co-transfected with
plasmids encoding the chimeric Apobec3G bait construct (A3G bait) and the prey constructs encoding for proteins Vif, VifSLQ144-146AAA
(VifSLQprey), VifC133S, A3G or A3G-D128K fused to the gp130 chain, combined with the pXP2d2-rPAP1-luci reporter. The transfected cells
were either stimulated for 24h with Epo or were left untreated (NS, not stimulated). Luciferase measurements were performed in triplicate. Data are
presented as either absolute luciferase counts per second (cps) or fold induction (Epo stimulated/NS) of luciferase activity. Western blot control of
the diﬀerent prey constructs in the experiment is shown.
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the interaction with Vif (Figure 3, 4 and 6). In Apobec3G,
T32 is phosphorylated by protein kinase A, reducing the
interaction with Vif (46). A T32Q mutation increases the
MAPPIT interaction with the VifSLQ prey and has no
eﬀect on the Apobec3G homodimerization interaction
(Figure 9 and Table 1). A K99D mutation similarly
aﬀects the MAPPIT A3G-Vif interaction, without aﬀect-
ing the homodimerization of Apobec3G (Table 1).
We mapped the position of D128, P129, T32 and K99
on our dimer model (Figures 7 and 8). D128 is located at
the edge of the conserved Apobec3G–Apobec3G interface.
P129, T32 and K99 are all found at the edge of the interface
and are surface exposed. P129 of one monomer comes very
close to T32 of another monomer (7.5A ˚ ). These residues
may thus be part of a composite Vif-binding site formed by
interaction of two Apobec3G N-terminal domains.
DISCUSSION
Vif binds to Apobec3G and Apobec3G homodimerize
via an RNA-dependent mechanism (27,40,47). The
N-terminal deaminase domain of Apobec3G was
reported to play an important role in both interactions
(4). Huthoﬀ et al. (27) recently proposed a homology
model for an Apobec3G dimer and demonstrated the
importance of the area around W127 for RNA-mediated
dimerization of Apobec3G. Mutations of Y124 and W127
inhibit incorporation of Apobec3G into virion particles
and oligomerization (29). Arginine 24, 30 and 136
are important for interaction with RNA and for
RNA-mediated oligomerization. Mutation of these
arginines reduces packing of Apobec3G into the
virion (27).
We built a dimer model for the N-terminal domain
of Apobec3G where W127 is involved in head-to-head
interactions, consistent with the model proposed by
Huthoﬀ et al. The residues in the predicted interface
are well conserved between Apobec3G and Apobec3F,
suggesting a similar mode of homodimerization for
Apobec3F. The zone of sequence identity between
Apobec3G and Apobec3F extends beyond the model
interface and includes a subzone that centers around
W127 and a subzone formed by more N-terminal
residues including Y19, Y22 and T32. Interestingly,
these two subzones coincide with two regions that deter-
mine subcellular localization of Apobec3G. Residues
113–128 were shown to be important for nuclear exclusion
and cytoplasmic retention of Apobec3G, while mutations
of Y19, Y22 and T32, F126 and W127 demonstrated
the importance of these two regions for maintaining
the cytoplasmic localization (48,49). Probably, the
oligomerization status of Apobec3G and Apobec3F
plays a determining role in their localization.
MAPPIT can be used as a valid tool to study protein–
protein interactions of potential therapeutic targets.
Previously we employed MAPPIT in a detailed examina-
tion of the dimerization of HIV-1 reverse transcriptase in
intact human cells (50). We here used MAPPIT to analyze
the Apobec3G-Apobec3G and the Apobec3G–Vif interac-
tions. The D128K and P129A mutations speciﬁcally
disrupt the Apobec3G–Vif interaction. Mutations of
R122, Y124 and Y125 or W127 inhibit the Apobec3G–
Apobec3G interaction. These data are in accordance with
previous reports (26,27,29,42–45), validating MAPPIT
as a reliable tool to study the Apobec3G–Apobec3G
and Apobec3G–Vif interaction. In line with this,
alphascreen
TM experiments conﬁrmed the role of W127
in the Apobec3G homodimerization, as the W127A
mutation strongly decreases the interaction. The A3G
homodimerization is abrogated by RNAseA treatment,
conﬁrming that the interaction via W127 is dependent
on RNA.
We tested the importance of the predicted Apobec3G
homodimerization interface for the interaction with Vif.
We found that all mutations that strongly reduce the
Apobec3G–Apobec3G interaction also strongly reduce
the interaction with Vif. These data seem to contradict
the three previous reports that show that degradation of
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Figure 4. Hek293T cells were transiently co-transfected with plasmids
encoding the chimeric Apobec3G WT or mutant constructs and
the Apobec3G WT or mutant prey constructs, combined with the
pXP2d2-rPAP1-luci reporter. The transfected cells were either
stimulated for 24 h with Epo or were left untreated (NS, not
stimulated). Luciferase measurements were performed in triplicate.
Data are expressed as fold induction (Epo stimulated/NS) of luciferase
activity. Western blot control of the prey constructs is shown.
Nucleic Acids Research,2010, Vol.38, No. 6 1907Apobec3G by Vif is not aﬀected by mutations in the
proposed Apobec3G homodimerization interface: (i)
Huthoﬀ et al. (27) found that point mutations in the 122
RLYYFW 127 motif have no eﬀect on Apobec3G degra-
dation by Vif; (ii) Bulliard et al. (31) reported that a
W94L and W127A mutation in the head-to-head interface
do not interfere with Apobec3G degradation by Vif; and
(iii) Shirakawa et al. (31,46) demonstrated that an R24A
mutant shows normal Vif binding and normal degrada-
tion by Vif. In our MAPPIT experiments, an R24S
mutation severely reduces both Apobec3G dimerization
and Vif binding.
However, an important role for the homodimerization
interface for Vif binding is in line with a recent study by
Gooch and Cullen (26). The RLYYFW motif in
Apobec3G is replaced by RIYDY in Apobec3A, which
is not a target of Vif. Gooch and Cullen (26) reported
that mutation of 124 YYFW 127 in Apobec3G to the
corresponding Apobec3A sequence YDY decreased Vif
binding. This Apobec3G mutant is not targeted for deg-
radation by Vif. The mutation drastically disrupts the
Apobec3G–Apobec3G and Apobec3G–Vif interactions
in our MAPPIT assay (Table 1).
Conversely, mutation of the RIYDY sequence in
Apobec3A to RIYYFW turns Apobec3A into a target
for Vif binding (26). This mutation introduces a
RIYYFWDP sequence into Apobec3A, which is similar
to the RLYYFWDP sequence in Apobec3G. The
RI/LYYFWDP sequence may be central for recognition
by Vif. Unfortunately, it is at present unclear whether the
RIYYFW mutation in Apobec3A leads to dimerization
of Apobec3A.
Diﬀerent regions in Vif, 40 YRHHY 44 and 14 DRMR
17 were reported to be essential for binding to Apobec3G
and 3F, respectively (51). While Vif associates with
the N-terminal domain of Apobec3G, Vif binds to
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Figure 5. Hek293T cells were transiently co-transfected with plasmids encoding the E- and Flag tagged Apobec3G WT or mutants, a BC-box
deﬁcient mutant of CIS was included as a negative control. The transfected cells were lysed after 48h and protein interactions were detected with the
alphascreen FLAG
TM (M2) detection kit (Perkinelmer) with or without RNAse treatment.
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Figure 6. Hek293T cells were transiently co-transfected with plasmids encoding the chimeric Apobec3G WT or mutant constructs and the Apobec3G
or VifSLQ prey constructs, combined with the pXP2d2-rPAP1-luci reporter. The transfected cells were either stimulated for 24h with Epo or were
left untreated (NS, not stimulated). Luciferase measurements were performed in triplicate. Data are expressed as fold induction (Epo stimulated/NS)
of luciferase activity. Western blot control of the diﬀerent prey constructs in the experiment is shown.
1908 Nucleic Acids Research, 2010,Vol.38, No. 6the C-terminal domain of Apobec3F (52). Interestingly,
the C-terminal domain of Apobec3F contains a
RLYYFWDTD sequence, which is almost identical to
the RLYYFWDPD sequence of Apobec3G.
Two models explain why mutations that aﬀect
Apobec3G dimerization also aﬀect Vif binding
(Figure 10).
In a ﬁrst model, Vif binds an Apobec3G monomer.
The Vif interaction site overlaps with the Apobec3G
head-to-head interface. This Vif-binding site would then
include residues R122, Y125, W127, D128 and P129.
In this model, Vif binding may compete with Apobec3G
dimerization.
In a second model, Vif binds to an Apobec3G dimer.
The Vif-binding site is composed of two interacting
Apobec3G monomers. Four residues aﬀect the
Apobec3G–Vif interaction without apparent eﬀects on
the Apobec3G dimerization. Mutation of D128 or P129
disrupts the interaction with Vif. Mutation of T32 or K99
increases interaction with Vif. In the Apobec3G dimer
model, T32 of one Apobec3G monomer comes close
to K99, D128 and P129 of the other Apobec3G
monomer. These four residues may be part of a
composed Vif-binding site.
In summary, we present a model where the N-terminal
domains of Apobec3G interact in a similar way as
Table 1. Overview of the eﬀect of mutations in the Apobec3G
MAPPIT bait on the interaction with the Apobec3G prey (left)
or VifSLQ prey (right)
ASA
(A ˚ 2)
Apobec3G–
Apobec3G
Apobec3G–
Vif
A3G %WT SD Vif %WT SD
V9A 0 100 4 74 21
R11S 0 60 21 97 56
M12A 0 12 5 20 5
R14S 0 146 49 188 69
Y19A 0 50 17 101 84
Y19AY22A 0/–26 1 1 7 7
N20A 0 52 10 63 20
Y22A –26 25 22 24 13
R24S –53 19 19 33 13
LS27-28A –59/–38 16 8 28 9
RR29-30SS –23/0 1 1 10 4
N31S –7 98 75 150 73
T32Q 0 138 65 242 121
T32D 0 153 92 181 92
T32E 0 126 84 136 39
W34A 0 112 59 72 41
R55A 0 69 17 81 70
K63E 0 220 109 228 103
W94A –12 4 2 25 23
TK98-99AS 0 177 97 409 264
TK98-99AD 0 181 140 785 397
K99D 0 79 44 263 72
R102A 0 1 0 6 2
RD102-103SS 0 182 194 143 148
RD102-103EK 0 368 160 532 5
TF106-107AA 0 151 166 124 76
E110S 0 377 188 328 20
E110K 0 365 180 453 201
D111K 0 35 29 26 29
R122S –48 1 0 7 5
L123A 0 3 2 26 14
Y124A –2 28 22 64 30
YY124-125SS –2/–38 1 1 11 7
YFW125-127DY –83/–22/–134 1 1 20 18
W127A –134 1 1 9 10
D128K –61 87 36 25 18
D128H –61 91 89 54 25
D128Q –61 68 46 38 16
P129A –36 159 66 45 48
D130A –48 104 48 54 58
QE132-133AA –8/0 53 11 53 10
R136A 0 43 20 76 60
S137A 0 71 71 190 61
F157A 0 3 0 24 25
YS166-167AA 0 102 67 121 94
F172A 0 3 2 17 17
W175A 0 7 7 24 22
Y181A –32 3 3 11 4
L184A –39 140 88 280 199
MAPPIT luciferase fold inductions for each mutant are expressed as
percentage of Wild Type Apobec3G bait. The averages of these percent
values of several independent MAPPIT experiments and standard
deviation (SD) are shown. Strongly increased or decreased values that
are signiﬁcantly diﬀerent from the WT in a paired t-test are indicated
by a color code. Red and orange indicate a 70 and 50% reduction of
the MAPPIT signal; green indicates a >200% increase of the MAPPIT
signal. Hek293T cells were transiently co-transfected with plasmids
encoding the chimeric Apobec3G WT or mutant Apobec3G bait con-
structs and Vif or Apobec3G prey constructs, combined with the
pXP2d2-rPAP1-luci reporter. The transfected cells were either
stimulated for 24h with Epo or were left untreated (NS, not
stimulated). Luciferase measurements were performed in triplicate.
Data are expressed as a percentage of the WT fold inductions
(stimulated/NS). ASA gives the decrease of the water accessibility
(in square Angstro ¨ ms) of the mutated residue sidechains upon interac-
tion of two monomers via the head-to-head interface. Residue
sidechains that get buried in the interface have a negative ASA.
A
B
P129
T32
K99
P129
T32
K99
Figure 7. Eﬀect of mutations on A3G–A3G (A) and A3G–vif (B) inter-
actions. (A) Residues are colored according to the eﬀect of mutation
of the residue on the Apobec3G–Apobec3G MAPPIT interaction.
(B) Residues are colored according to the eﬀect of mutation on the
Apobec3G–Vif MAPPIT interaction. The eﬀect on the MAPPIT signal
in(A) and (B) is indicated by color as in Table 1. red is <30% of WT;
orange is <50% of WT; green is >200% of WT; black: the other
mutants.
Nucleic Acids Research,2010, Vol.38, No. 6 1909Apobec2. Using MAPPIT and alphascreen
TM, we demon-
strate that the interaction is mediated by RNA and that
mutations in the head-to-head interface inhibit Vif
binding. The dimer interface of Apobec3G is almost iden-
tical in the N-terminal domain of Apobec3F, suggesting
that Apobec3G and 3F can form similar complexes.
Mutations of T32, K99, D128 or P129 at the brim of
the head-to-head interface in Apobec3G speciﬁcally
aﬀect Vif binding, and these residues may be part of a
Vif-binding site that covers parts of two
interacting N-terminal domains. Mutations in the
head-to-head interface interfere with interaction of
Apobec3G with gag and with incorporation of
Apobec3G into the virion (26,27,29). Vif may select
Apobec targets that incorporate into virions via binding
to the dimer interface area.
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